KROS vs. AMPH, RNA, PTCT, MRVI, GLPG, NAMS, GERN, RCKT, VERA, and SDGR
Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Amphastar Pharmaceuticals (AMPH), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Maravai LifeSciences (MRVI), Galapagos (GLPG), NewAmsterdam Pharma (NAMS), Geron (GERN), Rocket Pharmaceuticals (RCKT), Vera Therapeutics (VERA), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry.
Keros Therapeutics (NASDAQ:KROS) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.
Keros Therapeutics presently has a consensus price target of $86.00, suggesting a potential upside of 48.63%. Amphastar Pharmaceuticals has a consensus price target of $66.00, suggesting a potential upside of 60.54%. Given Amphastar Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Keros Therapeutics.
Amphastar Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a net margin of 21.34% compared to Keros Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.95% beat Keros Therapeutics' return on equity.
Amphastar Pharmaceuticals received 346 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 66.84% of users gave Amphastar Pharmaceuticals an outperform vote while only 66.10% of users gave Keros Therapeutics an outperform vote.
Keros Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 28.0% of Keros Therapeutics shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Keros Therapeutics. MarketBeat recorded 4 mentions for Amphastar Pharmaceuticals and 0 mentions for Keros Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.71 beat Keros Therapeutics' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
Summary
Amphastar Pharmaceuticals beats Keros Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Keros Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Keros Therapeutics Competitors List
Related Companies and Tools
